At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 17 enrolled
Drug / intervention
SCH 497079 +2 moredrug
Likely dose
SCH 497079 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-controlled, Three-Way Crossover Study to Evaluate the Effect of SCH 497079 on Metabolic Parameters and to Determine the Influence of Race/Ethnic Origin on Therapeutic Response
In Brief
A Phase 1 clinical trial evaluating SCH 497079, Placebo, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 17 participants.
Detailed Summary
The purpose of this study is to evaluate the effect of SCH 497079 on metabolic parameters and to determine the influence of race/ethnic origin on therapeutic response.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedMay 2008
Primary CompletionDec 2008
TodayJul 2026
First PostedMay 7, 2008
Enrollment StartApr 17, 2008
Primary CompletionDec 11, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 18.2 years ago
Interventions
SCH 497079drug
SCH 497079 100 mg capsule, administered orally, once daily for 4 weeks
Placebodrug
Placebo capsules matching SCH 497079, administered orally, once daily for 4 weeks
Metformindrug
Metformin extended release 750 mg, 2 tablets administered orally, once daily for 4 weeks (1500 mg total daily dose)